© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
8442 SETTLERS PSGE
April 15, 2008
The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).